On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
WednesdayMay 08, 2013 3:40 pm

Gold Dynamics Corp. (GLDN) Updates Markets on E&D of Hoyle North Gold Property in Prolific Timmins Mining Area, Ontario

Gold Dynamics, the rapidly emerging precious minerals developer currently focused on their 32-claim unit Hoyle North property, representing some 4.6 square miles of land in the legendary Timmins gold mining area (Ontario), reported today that they are moving ahead with the next phase of property development, including retention of a pro geologist for the advisory team. GLDN will be pulling out all the stops in the coming year, capitalizing on all the exploration work that has been done in the last two years and they are already hard at work pouring over the VTEM Survey and soil sample results in…

Continue Reading

FridayApr 19, 2013 8:13 am

William J. Keaneally Appointed as CFO at CTP Partners Executive Search, Inc. (CTP)

Leading executive search firm CTPartners Executive Search announced yesterday that William J. Keneally has been appointed as its Chief Financial Officer. As CFO, Mr. Keaneally will oversee CTPartners’ global finance functions. That includes: financial planning and analysis, controllership, tax, treasury, and investor relations. He will report directly to CTPartners’ CEO, Brian Sullivan. Mr. Sullivan remarked, “Bill brings over 25 years of experience in global finance, accounting and the public capital markets to the CTPartners team. Bill will make a significant contribution to our financial planning and reporting process, and acquisition analysis, both of which are integral parts of our growth…

Continue Reading

WednesdayApr 10, 2013 1:50 pm

VentriPoint Diagnostics Ltd. (VPTDF) Changes the Way Doctors Look at Hearts

VentriPoint Diagnostics, a Seattle-based heart analysis technology company, is in the process of changing the way hearts are analyzed, a significant venture given the size of the market. According to the American Heart Association, there are approximately 80 million U.S. adults experiencing some form of cardiovascular disease, representing an annual total cost of nearly $500 billion. However, in spite of advances in ultrasound, MRI, and other non-invasive diagnostic technologies, there are currently a number of problems with accurate heart diagnosis. In particular, accurate analysis of what is called the “right heart” has been problematic. The right side of the heart…

Continue Reading

WednesdayMar 27, 2013 1:46 pm

Catalyst Pharmaceutical Partners, Inc. (CPRX) Receives Recommendation from Data Monitoring Committee Regarding Phase III Clinical Trial of Firdapse

Today, specialty pharmaceutical company Catalyst Pharmaceutical Partners announced that the independent data monitoring committee (DMC) overseeing its ongoing pivotal Phase III clinical trial of Firdapse recommended on March 25 that the company continue the trial as planned based on the committee’s review of safety and clinical data from the trial. Firdapse is currently being evaluated in the United States and Europe to treat Lambert-Easton Myasthenic Syndrome (LEMS). The DMC is comprised of experts who are responsible for independently reviewing accumulated clinical safety and efficacy data obtained in Catalyst’s clinical trial, for the safety of participants and future patients. The committee…

Continue Reading

MondayMar 18, 2013 8:26 am

Omni Bio Pharmaceutical, Inc. (OMBP) Reports Favorable Mouse Study Results of Fc-AAT Molecule

Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of novel uses of alpha-1 antitrypsin (AAT), today reported study results for the company’s recombinant molecule, Fc-AAT, suggesting its potential to treat refractory gout and other inflammatory conditions. Leo A. B. Joosten, PhD, of the Radboud University Medical Center, Nijmegen, The Netherlands, detailed the findings of several of his studies in mouse models of gouty arthritis, which showed that Fc-AAT: • Suppressed pro-inflammatory responses • Exhibited a reduction of 85% in these parameters at a relatively low dose of 50 µg (2 mg/kg per mouse) that was at least as…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered